

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application No.	10/563,731
		Filing Date	January 6, 2006
		First Named Inventor	Else Agger
		Art Unit	1645
<i>(Multiple sheets used when necessary)</i>		Examiner	Nina Archie
SHEET 1 OF 1		Attorney Docket No.	PLOUGH.001APC

**U.S. PATENT DOCUMENTS**

#### FOREIGN PATENT DOCUMENTS

## NON-PATENT LITERATURE DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	3	Gregoriadis, G. (1995) Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 13:527-537.	
	2	Hilgers et al. (1991) DDA as an immunological adjuvant. Res. Immunol. 143:494-503.	
	3	Koike et al. (1998) Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine. 16(20):1982-1989	
	4	Moingeon et al. (2001) Towards the rational design of Th1 adjuvants. Vaccine. 19:4363-4372.	

8355497/bab/010810

Examiner Signature	/Nina Archie/	Date Considered	1/14/2010
--------------------	---------------	-----------------	-----------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**\*Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in the box if the following statement is true. If false, draw a line through the entire statement.